To perform this analysis, a cohort of BC patients comprising all stages (I, II, III, and IV) of BC disease was selected (for clinicopathological details please refer to Table 1) and the plasma levels of NE, EPI, and CORT were quantified by ELISA (Figure 1). This evidence concerns the gene CORT and breast cancer.